rosiglitazone has been researched along with acid phosphatase in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M | 1 |
| Alves, JB; Alves, PM; Campos-Júnior, JC; Cunha, FQ; Gonçalves, RB; Hassumi, MY; Kawai, T; Napimoga, MH; Silva-Filho, VJ; Vieira, SM | 1 |
2 other study(ies) available for rosiglitazone and acid phosphatase
| Article | Year |
|---|---|
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis.
Topics: Acid Phosphatase; Administration, Oral; Alveolar Bone Loss; Animals; Cell Differentiation; Cell Line; Hypoglycemic Agents; Immunohistochemistry; Isoenzymes; Male; Osteoclasts; Osteogenesis; Periodontitis; PPAR gamma; RANK Ligand; Rats; Rats, Wistar; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazolidinediones | 2009 |